Loading...
Please wait, while we are loading the content...
Similar Documents
Thoracic positron emission tomography: 18F-fluorodeoxyglucose and beyond.
| Content Provider | Europe PMC |
|---|---|
| Author | Jaykel, Timothy J. Clark, Michael S. Adamo, Daniel A. Welch, Brain T. Thompson, Scott M. Young, Jason R. Ehman, Eric C. |
| Copyright Year | 2020 |
| Abstract | Ongoing technologic and therapeutic advancements in medicine are now testing the limits of conventional anatomic imaging techniques. The ability to image physiology, rather than simply anatomy, is critical in the management of multiple disease processes, especially in oncology. Nuclear medicine has assumed a leading role in detecting, diagnosing, staging and assessing treatment response of various pathologic entities, and appears well positioned to do so into the future. When combined with computed tomography (CT) or magnetic resonance imaging (MRI), positron emission tomography (PET) has become the sine quo non technique of evaluating most solid tumors especially in the thorax. PET/CT serves as a key imaging modality in the initial evaluation of pulmonary nodules, often obviating the need for more invasive testing. PET/CT is essential to staging and restaging in bronchogenic carcinoma and offers key physiologic information with regard to treatment response. A more recent development, PET/MRI, shows promise in several specific lung cancer applications as well. Additional recent advancements in the field have allowed PET to expand beyond imaging with 18F-flurodeoxyglucose (FDG) alone, now with the ability to specifically image certain types of cell surface receptors. In the thorax this predominantly includes 68Ga-DOTATATE which targets the somatostatin receptors abundantly expressed in neuroendocrine tumors, including bronchial carcinoid. This receptor targeted imaging technique permits targeting these tumors with therapeutic analogues such as 177Lu labeled DOTATATE. Overall, the proper utilization of PET in the thorax has the ability to directly impact and improve patient care. |
| ISSN | 20721439 |
| Journal | Journal of Thoracic Disease |
| Volume Number | 12 |
| PubMed Central reference number | PMC7711422 |
| Issue Number | 11 |
| PubMed reference number | 33282403 |
| e-ISSN | 20776624 |
| DOI | 10.21037/jtd-2019-cptn-09 |
| Language | English |
| Publisher | AME Publishing Company |
| Publisher Date | 2020-11-01 |
| Access Restriction | Open |
| Rights License | Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0. 2020 Journal of Thoracic Disease. All rights reserved. |
| Subject Keyword | Positron emission tomography (PET) positron emission tomography/computed tomography (PET/CT) positron emission tomography/magnetic resonance imaging (PET/MRI) pulmonary nodule bronchogenic carcinoma |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pulmonary and Respiratory Medicine |
